BACKGROUND: Depot delivery of antimicrobial agents is used for treatment and prevention of bacterial orthopaedic infections; there is little information regarding newer antifungal agents and their potential use in polymethylmethacrylate (PMMA) depot delivery. QUESTIONS/PURPOSES: We determined the percent of anidulafungin or voriconazole present after polymerization in PMMA beads loaded with anidulafungin or voriconazole, and we assessed elution of anidulafungin or voriconazole from beads loaded with anidulafungin or voriconazole. MATERIALS AND METHODS: Beads containing 7.5% anidulafungin or voriconazole were pulverized and incubated in Kreb's ringer buffer for 48 hours; the buffer was assayed for anidulafungin or voriconazole concentration. The in vitro release of anidulafungin and voriconazole from PMMA beads loaded with 7.5% anidulafungin or voriconazole was determined in triplicate in a continuous flow chamber. RESULTS: 0.7% of anidulafungin and 5.6% of voriconazole loaded in the beads were detected after polymerization. No anidulafungin was detected in the elution studies. The mean peak voriconazole concentration in the elution studies was 0.9 μg/mL. CONCLUSIONS: Anidulafungin may not be suitable for depot delivery in PMMA.
BACKGROUND: Depot delivery of antimicrobial agents is used for treatment and prevention of bacterial orthopaedic infections; there is little information regarding newer antifungal agents and their potential use in polymethylmethacrylate (PMMA) depot delivery. QUESTIONS/PURPOSES: We determined the percent of anidulafungin or voriconazole present after polymerization in PMMA beads loaded with anidulafungin or voriconazole, and we assessed elution of anidulafungin or voriconazole from beads loaded with anidulafungin or voriconazole. MATERIALS AND METHODS: Beads containing 7.5% anidulafungin or voriconazole were pulverized and incubated in Kreb's ringer buffer for 48 hours; the buffer was assayed for anidulafungin or voriconazole concentration. The in vitro release of anidulafungin and voriconazole from PMMA beads loaded with 7.5% anidulafungin or voriconazole was determined in triplicate in a continuous flow chamber. RESULTS: 0.7% of anidulafungin and 5.6% of voriconazole loaded in the beads were detected after polymerization. No anidulafungin was detected in the elution studies. The mean peak voriconazole concentration in the elution studies was 0.9 μg/mL. CONCLUSIONS:Anidulafungin may not be suitable for depot delivery in PMMA.
Authors: David Silverberg; Pradeep Kodali; Joseph Dipersio; Raymond Acus; Michael Askew Journal: Clin Orthop Relat Res Date: 2002-10 Impact factor: 4.176
Authors: Emily W Hall; Mark S Rouse; David J Jacofsky; Douglas R Osmon; Arlen D Hanssen; James M Steckelberg; Robin Patel Journal: Diagn Microbiol Infect Dis Date: 2004-12 Impact factor: 2.803
Authors: Archie C Perry; Mark S Rouse; Yasmin Khaliq; Kerryl E Piper; Arlen D Hanssen; Douglas R Osmon; James M Steckelberg; Robin Patel Journal: Clin Orthop Relat Res Date: 2002-10 Impact factor: 4.176
Authors: F Marco; C Danés; M Almela; A Jurado; J Mensa; J Puig de la Bellacasa; M Espasa; J A Martínez; M T Jiménez de Anta Journal: Diagn Microbiol Infect Dis Date: 2003-08 Impact factor: 2.803
Authors: Paloma Anguita-Alonso; Mark S Rouse; Kerryl E Piper; David J Jacofsky; Douglas R Osmon; Robin Patel Journal: Clin Orthop Relat Res Date: 2006-04 Impact factor: 4.176
Authors: Ryan B Miller; Alex C McLaren; Christine Pauken; Henry D Clarke; Ryan McLemore Journal: Clin Orthop Relat Res Date: 2013-01 Impact factor: 4.176
Authors: Alexander M Tatara; Allison J Rozich; Panayiotis D Kontoyiannis; Emma Watson; Nathaniel D Albert; George N Bennett; Antonios G Mikos Journal: J Mater Sci Mater Med Date: 2018-05-11 Impact factor: 3.896